CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

Seeking Alpha • Oct 27, 2026

Australia's CSL appoints Deborah Waterhouse as CEO

Australian biotechnology company CSL on Wednesday named GSK executive Deborah Waterhouse as its next chief executive ‌and managing director, effective February, seeking to turn a budding share-price recovery into sustained earnings growth.

Reuters • Oct 21, 2026

CSL appoints Deborah Waterhouse as CEO & Managing Director

MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive global search process conducted by CSL's Board of Directors.

PRNewsWire • Oct 21, 2026

HRMY vs. CSLLY: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Oct 6, 2026

CSL strikes US$1.6 billion licensing deal for rare disease drug

CSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting rare kidney and liver diseases. The deal gives CSL rights to advance the drug, which is currently in Phase 2 trials for ANCA-associated vasculitis, a rare autoimmune disease that can cause severe kidney damage.

Proactive Investors • Oct 5, 2026

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases. Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients with ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease.

PRNewsWire • Oct 4, 2026

Australia's CSL taps Amazon's cloud unit to boost research pipeline

Australian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud ​arm to harness AI and cloud ‌technology across its research and clinical development pipeline.

Reuters • Sep 29, 2026

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept.

PRNewsWire • Sep 10, 2026

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

Zacks Investment Research • Sep 1, 2026

Trump administration to announce drug pricing deals

U.S. President Donald ​Trump is expected to announce a new round of drug-pricing agreements on Monday, a White ‌House official said, part of a push to make healthcare more affordable for Americans.

Reuters • Aug 31, 2026